Johnson & Johnson $JNJ Shares Bought by Consolidated Planning Corp

Consolidated Planning Corp grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 19.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,422 shares of the company’s stock after acquiring an additional 1,055 shares during the quarter. Consolidated Planning Corp’s holdings in Johnson & Johnson were worth $981,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Highline Wealth Partners LLC boosted its position in shares of Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after buying an additional 86 shares during the period. Stone House Investment Management LLC purchased a new stake in shares of Johnson & Johnson in the first quarter worth about $47,000. 1248 Management LLC purchased a new stake in shares of Johnson & Johnson in the first quarter worth about $48,000. von Borstel & Associates Inc. purchased a new position in Johnson & Johnson in the first quarter valued at about $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in Johnson & Johnson in the first quarter valued at about $52,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Trading Up 1.4%

Shares of NYSE JNJ opened at $188.51 on Friday. The stock’s 50 day moving average price is $176.18 and its two-hundred day moving average price is $162.83. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $189.78. The stock has a market capitalization of $453.98 billion, a P/E ratio of 20.16, a PEG ratio of 2.37 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $23.74 billion for the quarter, compared to analysts’ expectations of $22.85 billion. During the same quarter in the prior year, the firm posted $2.82 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is presently 55.61%.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. JPMorgan Chase & Co. increased their price target on Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a report on Tuesday, September 16th. The Goldman Sachs Group increased their price target on Johnson & Johnson from $185.00 to $186.00 and gave the company a “buy” rating in a report on Friday, September 19th. Bank of America increased their price target on Johnson & Johnson from $175.00 to $198.00 and gave the company a “neutral” rating in a report on Friday. Morgan Stanley increased their price target on Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. Finally, Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $187.47.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.